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Background: High-grade gliomas (HGGs) express somatostatin receptors (SSTR), rendering them candidates for
peptide receptor radionuclide therapy (PRRT). Our purpose was to evaluate the potential of 68Ga-DOTA-1-Nal3-octreotide
(68Ga-DOTANOC) or 68Ga-DOTA-Tyr3-octreotide (68Ga-DOTATOC) to target SSTR subtype 2 (SSTR2) in HGGs, and to study
the association between SSTR2 expression and established biomarkers.
Methods: Twenty-seven patients (mean age 52 years) with primary or recurrent HGG prospectively underwent
68Ga-DOTA-peptide positron emission tomography/computed tomography (PET/CT) before resection. Maximum
standardized uptake values (SUVmax) and receptor binding potential (BP) were calculated on PET/CT and disruption of
blood–brain barrier (BBB) from contrast-enhanced T1-weighted magnetic resonance imaging (MRI-T1-Gad). Tumor
volume concordance between PET and MRI-T1-Gad was assessed by Dice similarity coefficient (DC) and correlation by
Spearman’s rank. Immunohistochemically determined SSTR2 status was compared to receptor imaging findings,
prognostic biomarkers, and survival with Kruskal-Wallis, Pearson chi-square, and multivariate Cox regression, respectively.
Results: All 19 HGGs with disrupted BBB demonstrated tracer uptake. Tumor SUVmax (2.25 ± 1.33) correlated with
MRI-T1-Gad (r = 0.713, P = 0.001) although DC 0.41 ± 0.19 suggested limited concordance. SSTR2 immunohistochemistry
was regarded as positive in nine HGGs (32%) but no correlation with SUVmax or BP was found. By contrast, SSTR2
expression was associated with IDH1 mutation (P = 0.007), oligodendroglioma component (P = 0.010), lower grade
(P = 0.005), absence of EGFR amplification (P = 0.021), and longer progression-free survival (HR 0.161, CI 0.037 to 0.704,
P = 0.015).
Conclusions: In HGGs, uptake of 68Ga-DOTA-peptides is associated with disrupted BBB and cannot be predicted by
SSTR2 immunohistochemistry. Thus, PET/CT shows limited value to detect HGGs suitable for PRRT. However, high SSTR2
expression portends favorable outcome along with established biomarkers such as IDH1 mutation.
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High-grade gliomas (HGGs) are the most common pri-
mary malignant brain tumors with a dismal prognosis
[1]. Few treatment options are available in HGGs at the
time of recurrence which typically is local. Beneficial re-
sponse to peptide receptor radionuclide therapy (PRRT)
targeting somatostatin receptors has been observed in
pilot studies including both low-grade (WHO grade II)
and high-grade (WHO grade III and IV) gliomas [2,3].
Additionally, Heute et al. reported encouraging results
with recurrent glioblastomas locally treated with 90Y-
DOTATOC, with a complete remission in one patient
[4]. Therefore, PRRT remains an appealing treatment
modality especially in recurrent HGGs. However, PRRT
is technically demanding and careful selection of pa-
tients who are likely to respond is therefore required.
Somatostatin receptor (SSTR) expression in HGGs is
controversial. While autoradiographic binding studies
have shown no SSTR expression in glioblastomas, im-
munohistochemistry (IHC) and western blot have de-
tected increased expression of subtypes SSTR1, SSTR2,
and SSTR3 [5,6]. Therefore, an in vivo method to iden-
tify SSTR2 expression, the most abundant subtype, in pa-
tients who are candidates for PRRT is required. While
scintigraphic studies have shown variable uptake of
octreotide analogs in gliomas, we are not aware of pro-
spective studies on 68Ga-DOTANOC or 68Ga-DOTA-
TOC uptake in gliomas with positron emission
tomography (PET), which has superior sensitivity com-
pared to scintigraphy in detecting SSTR2-positive neuro-
endocrine tumors [7,8].
Our understanding on the genetic alterations in gli-
omas has led to the recognition of several molecular
subtypes with distinct clinical, prognostic, and imaging
characteristics [9,10]. IDH1 mutation, MGMT promoter
methylation, and 1p/19q co-deletion are the three mo-
lecular markers included today in routine assessment of
gliomas due to their diagnostic, prognostic, or predictive
value [11]. An association between these molecular bio-
markers and SSTR2 expression in HGGs, however, has
not been studied before.
We aimed to prospectively study the potential of 68Ga-
DOTANOC and 68Ga-DOTATOC to target SSTR2 in
HGGs and to detect HGGs suitable for PRRT in vivo.
We hypothesized that SSTR2 expression in HGGs could be
quantified with dynamic positron emission tomography/
computed tomography (PET/CT) using 68Ga-DOTA-
peptides. Also, our aim was to characterize SSTR2 expres-
sion in HGGs in relation to prognostic markers such as
IDH1 mutation.
Methods
Twenty-seven patients with radiologically suspected pri-
mary (n = 17) or recurrent (n = 10) HGG scheduled fortumor resection between 2011 and 2013 were prospect-
ively enrolled (mean age 52 years; 17 women and 10
men). PET/CT was performed prior to surgical resection
with a mean interval of 19 days. Additionally, one pa-
tient with primary HGG was included in SSTR2 IHC
analysis without performing PET/CT. 68Ga-DOTANOC
replaced 68Ga-DOTATOC as the tracer in practice after
first three patients due to poor availability of the DOTA-
TOC precursor. Patient characteristics are presented in
Table 1. The study was approved by the Ethics Commit-
tee of the Hospital District of Southwest Finland and the
Finnish Medicines Agency. All patients gave written in-
formed consent before participation. The study has been
registered at ClinicalTrials.gov (NCT01460706).
PET/CT with 68Ga-DOTA-peptides and MRI
68Ga-DOTA-peptides were synthesized as previously de-
scribed [12]. Radiochemical purity and specific activity
(mean) was 99.9% and 31.5 GBq/μmol for 68Ga-DOTA-
NOC, and 96.5% and 26.8 GBq/μmol for 68Ga-DOTA-
TOC, respectively. PET/CT of the brain was performed
using a GE Discovery VCT PET/CT Scanner (General
Electric Medical Systems, Pewaukee, WI, USA). Dy-
namic PET was acquired over 60 min (8 × 15-, 6 × 30-,
5 × 180-, 4 × 300-, and 2 × 600-s frames) after intraven-
ously injected 68Ga-DOTANOC (123 MBq, median) or
68Ga-DOTATOC (130 MBq, median). Low-dose CT
(120 kV, 10 to 95 mA, noise index 25, slice thickness
3.75 mm) was used for attenuation correction. PET im-
ages were reconstructed (256 × 256 matrix, OSEM3D, 3
iterations, 28 subsets, 4.8-mm Hanning postfilter) yield-
ing a pixel size of 1.4 mm. A duration of 60 min was de-
termined after 90-min dynamic PET performed to one
patient (no. 13) and 5-min static scans performed to three
patients (nos. 11, 12, and 23) 96 min post-injection con-
firmed that tumor uptake did not increase after 60 min.
Clinical preoperative MRI nearest in time to PET scan
(mean interval 14 days) was employed, and post-contrast
T1-weighted images (MRI-T1-Gad) were used to define
the tumor volume with contrast enhancement. MRI
scanners and parameters used are listed in Online Re-
source 1.
Image evaluation
Analyses were performed using in-house developed soft-
ware (Carimas 2.7; http://www.turkupetcentre.fi/cari-
mas/). PET and MRI-T1-Gad images were co-registered,
and spherical volumes of interest (VOIs) were manually
placed over the tumor area with maximum activity.
VOIs for contralateral normal brain white matter, nasal
mucosa, pituitary gland, and skin of the occiput were
also defined, and maximum standardized uptake values
(SUVmax) were calculated (SUV = [Tissue radioactivity
concentration (Bq/ml) × Body weight (g)]/Injected dose
Table 1 Clinical data, imaging abnormalities, and SSTR2 expression
Clinical data Imaging abnormalities SSTR2
Pt no Age/sex Stage Previous therapy Gr Dg PFS (months) OS (months) Follow-up (months) VT1-Gad (cm
3) DOTA SUVmax BP C H L
1 49/F Primary III A 29.4 0.57 TOC 0.79 −0.26 0 2 B
2 62/F Primary III A 14.4 1.71 NOC 1.22b NA 0 2 B
3 44/F Primary III A 21.0 0 NOC −c − 1 3 B
4 49/M Primary III A 13.0 0 NOC − − 3 3 C
5 57/F Primary III A 10.4 12.5 0.16 NOC 0.69 −0.47 0 0 −
6 18/M Primary III A 10.9 11.8 0 NOC − − 0 3 B
7 49/F Primary III A 10.7 0.81 NOC 0.69 d NA 1 3 C
8 32/F Primary III A 8.4 13.8 0 X X X 0 1 C
9 54/F Primary III O 13.6 27.7 0.03 NOC − − 3 3 B
10 60/M Primary III OA 21.6 0 NOC − − 3 3 B
11 71/M Primary IV GBMO 0 1.2 1.91 NOC 3.07 1.41 0 3 M
12 37/M Primary IV GBMO 21.0 4.32 NOC 0.99 −0.62 3 3 B
13 35/F Primary IV GBM 0 13.7 1.27 TOC 0.65 0.39 0 1 C
14 63/F Primary IV GBM 24.0 24.1 12.2 NOC 2.21 0.98 0 0 −
15 62/F Primary IV GBM 0 7.3 11.5 NOC 3.01 1.26 0 0 −
16 67/F Primary IV GBM 0 4.4 14.8 NOC 1.62 0.36 0 1 B
17 70/M Primary IV GBM 0 1.0 21.5 NOC 2.85 1.80 0 3 M
18 76/F Primary IV GS 0 0.9 34.7 NOC 3.73 1.75 0 3 M
19 28/M Recurrent S III A 81.2 106.1 0 NOC − − 1 3 B
20 51/M Recurrent S, RT III O 60.9 253.7 0 NOC − − 3 3 B
21 42/F Recurrent S, S, RT, S III OA 24.3 99.5 0 NOC − − 3 3 C
22 46/M Recurrent S, RT, C III OA 39.0 100.4 28.2 NOC 5.68 3.33 1 1 C
23 42/F Recurrent S, CRT IV GBM 24.0 37.1 0.04 TOC 0.46 −0.34 0 3 B
24 68/F Recurrent S, CRT IV GBM 23.1 26.3 27.9 NOC 2.40 1.57 0 0 −
25 64/F Recurrent S, CRT IV GBM 34.2 38.2 12.8 NOC 2.70 1.07 0 3 B
26 42/F Recurrent S, CRT IV GBM 5.5 13.6 28.0 NOC 2.44 2.28 0 3 B
27 61/F Recurrent S, RT IV sGBM 16.1 21.3 2.59 NOC 1.98 0.64 0 2 C
28 57/M Recurrent S, CRT IV GBM 11.0 27.5 3.03a NOC 3.26 2.33 0 3 B
Pt no, patient number; F, female; M, male; Gr, grade; Dg, diagnosis; A, astrocytoma; O, oligodendroglioma; OA, oligoastrocytoma; GBMO, glioblastoma with oligodendroglioma component; GBM, glioblastoma; sGBM,
secondary GBM; GS, gliosarcoma; S, surgery; RT, radiotherapy; C, chemotherapy (temozolomide); CRT, chemoradiotherapy with adjuvant temozolomide; Dx, dexamethasone; TOC, 68Ga-DOTATOC; NOC, 68Ga-DOTANOC;
−, no tracer uptake; X, no PET performed; NA, not applicable; C, intensity of most common staining (0 to 3); H, highest staining intensity (0 to 3); L, location of staining; C, cytoplasmic; M, membranous; B, both. aNo MRI
(cardiac pacemaker), tumor volume defined from contrast-enhanced CT; bstatic PET 28 to 58 min post-injection (mild claustrophobia); cdynamic PET discontinued at 53 min post-injection (dyspnea); ddynamic PET
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was used for further analyses.
Logan plot with skin as a reference tissue was used for
tracer kinetic modeling [13]. We used 5 min as the start-
ing point for linear regression model that was optimized
against the normalized tumor and reference tissue
time-activity curves (TAC), with the slope being the
distribution volume ratio (DVR). Binding potential (BP)
corresponds to the density of available receptors and is
calculated as BP = DVR − 1.
For comparison of tumor volume abnormalities in
PET and MRI-T1-Gad, the images were co-registered by
automatic fusion using iPlan RT Treatment Planning
Software (Brainlab, Munich, Germany). Tumor PET vol-
umes were contoured with a threshold of 40% SUVmax
(VPET). Contrast-enhanced tumor volume in MRI-T1-
Gad (VT1-Gad) was delineated by thresholding the enhan-
cing tumor volume on visual basis and then manually
subtracting the hyperintense volume on precontrast T1-
weighted images. Overlapping volumes between VPET
and VT1-Gad were determined, and Dice similarity coeffi-
cient (DC = [2 × Intersection]/[VPET + VT1-Gad]) was cal-
culated. A DC value of 1 indicates perfect similarity
between the volumes, while a value of 0 indicates no simi-
larity. Patient no. 5 was excluded from analysis due to low
SUVmax following failure in PET volume delineation.
Immunohistochemistry and molecular markers
Formalin-fixed paraffin-embedded tumor tissues were
sectioned at 3 μm and used for analyses. Antibodies for
IHC are listed in Table 2. MGMT promoter methylation
was studied by pyrosequencing [14], 1p/19q co-deletion
by fluorescent in situ hybridization, and EGFR amplifica-
tion by silver in situ hybridization [15].
SSTR2 IHC was scored first independently by an expe-
rienced neuropathologist (MG) and finally in consensus
with a second observer (AK) both blinded to PET data.Table 2 Primary antibodies and methods used for immunohis
Antibody Clone Manufacturer Method








Millipore, Billerica, MA Labvision Aut
EGFR 5B7 Ventana, Strasbourg, France Ventana Benc
IDH1 R132H H09 Dianova, Hamburg, Germany Ventana Benc
CD68 PG-M1 Dako, Glostrup, Denmark Ventana Benc
Ki67 30-9 Ventana, Strasbourg, France Ventana Benc
aSSTR2 + CD68 double staining.Double staining with UMB1 + CD68 was used to exclude
SSTR2 staining in microglia and macrophages and to
evaluate the number of these cells in the tumor speci-
men by counting all CD68-positive cells and tumor cells
in one representative high-power field. In diffuse gli-
omas, HE staining and IHC for IDH1 mutation assisted
in localizing tumor cells. Three scoring parameters were
reported for SSTR2 staining: the highest (minimum 10%
of tumor area), the most common staining intensity, and
the localization of staining (membranous, cytoplasmic,
or both). Staining intensities were classified as follows: 0
(negative), 1 (weak), 2 (moderate), and 3 (strong). The
same scoring parameters were used for EGFR IHC.
SSTR2 IHC was further categorized as positive if the
sum of the highest and most common staining inten-
sities was ≥4 and negative if the sum was <4.
Statistical analysis
Data are presented as mean ± SD. Pearson or Spearman’s
rank correlations were used between tracer uptake pa-
rameters and VT1-Gad. VPET and VT1-Gad were compared
with Mann–Whitney U test. The association between
SSTR2 status and molecular markers was studied with
Pearson chi-square analysis by cross-tabulations, and
difference in Ki67 with independent samples t test.
SSTR2 IHC and tracer uptake were compared with
Kruskal-Wallis. Kaplan-Meier curves with log-rank test
and univariate Cox regression were used to analyze
progression-free survival (PFS) and overall survival (OS).
Multivariate Cox regression (backward Wald) was per-
formed for PFS with SSTR2 status and tumor grade as var-
iables. PFS was defined as the time from the first surgical
resection (also for recurrent HGGs) to the first tumor
progression in MRI, deterioration in clinical symptoms,
or end of follow-up. OS was defined as the time from
the first surgical resection to death or end of follow-up.
Two-tailed P values <0.05 were regarded significant.tochemistry
Detection
hmark XT Autostainer
ical Systems, Strasbourg, France)
ultraVIEW Universal Detection Kit
(Ventana, Strasbourg, France)
ostainer (Thermo Scientific Inc,
I)
BrightVision Detection Kit (Immunologic,
Duiven, the Netherlands)
ostainer BrightVision Detection Kit
hmark XT Autostainer ultraVIEW Universal Detection Kit
hmark XT Autostainer ultraVIEW Universal Detection Kit
hmark XT Autostainera ultraVIEW Universal Detection Kit +
Universal Alkaline Phosphatase Red
Detection Kit (Ventana)a
hmark XT Autostainer ultraVIEW Universal Detection kit
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Mac (SPSS Inc., Chicago, IL, USA).
Results
All 19 HGGs with uptake demonstrated disrupted
blood-brain barrier (BBB) in MRI-T1-Gad whereas no
uptake was detected with intact BBB. Rapid peak in
tumor uptake was followed by gradual decline reaching
a plateau in 15 min (Figure 1A). Tumor SUVmax 30 to
60 min post-injection was 2.25 ± 1.33 (range 0.46 to
5.68), and it correlated with MRI-T1-Gad (r = 0.713, P =
0.001; Figure 1C). Tumor-to-skin SUVmax ratio was
2.12 ± 1.11.
Regression line of the Logan plot fitted to each data set
successfully. BP in HGGs with uptake was 1.03 ± 1.11, and
it correlated with tumor SUVmax (r = 0.868, P < 0.001;
Figure 1B) and tumor-to-skin SUVmax ratio (r = 0.956,
P < 0.001), implicating that SUVmax in this setting is a
good marker for specific receptor binding. Negative BP
values indicating lower tumor concentration of avail-
able receptors compared to reference tissue were found
in HGGs with SUVmax <1.0.
Difference in VPET (9.3 ± 9.5 cm
3) and VT1-Gad (12.9 ±
11.7 cm3) was nonsignificant (P = 0.559). [VPET]/[VT1-Gad]
tumor volume proportion was 1.05 ± 0.87. Dice similarity
coefficient between VPET and VT1-Gad was 0.41 ± 0.19.
Concordance and discordance between PET and MRI-T1-Figure 1 68Ga-DOTA-peptide uptake in PET and its comparison to enhancing
68Ga-DOTA-peptide uptake in HGGs compared to skin but distinctly lowe
to 60 min post-injection correlates to receptor binding potential (B) and
MRI-T1-Gad tumor volumes show apparent discordance in individual patGad tumor volumes in individual patients are demon-
strated in Figure 1D.
SSTR IHC and correlation to PET
SSTR2 expression in HGGs showed considerable vari-
ation (Table 1). When dichotomized, SSTR2 IHC was
regarded as positive in 8 anaplastic gliomas and 1
GBMO (32%) and as negative in 6 anaplastic gliomas
and 13 glioblastomas (GBMs) (68%). However, no correl-
ation with SUVmax or BP was found (Figure 2). In fact,
7 out of 8 HGGs with no 68Ga-DOTA-peptide uptake
were classified as SSTR2 positive, while 17 out of 19
HGGs with tracer uptake were classified as SSTR2 nega-
tive. Since most HGGs demonstrated patchy areas of
SSTR2 reactivity, though regarded as SSTR2 negative, we
studied whether SUVmax or BP associates to the highest
staining intensity observed. However, no association was
found (SUVmax P = 0.613; BP P = 0.655). SUVmax for
HGGs with membranous SSTR2 staining (3.21 ± 0.46)
was higher compared to that for HGGs demonstrating
both membranous and cytoplasmic staining (1.69 ±
1.01); however, the difference was not significant (P =
0.082). SSTR3 immunoreactivity was detected in cells
bordering necrosis in seven GBM samples. One glioma
(no. 2) displayed positive SSTR3 staining in approxi-
mately 30% of tumor cells. SSTR5 expression was not
detected in any of the tumor specimens studied. SSTR2tumor volume in MRI-T1-Gad. Time-activity curves show higher
r uptake when compared to pituitary gland (A). Tumor SUVmax at 30
to enhancing tumor volume in MRI-T1-Gad (C). However, PET and
ients (D) (corresponding to patient numbers in Table 1).
Figure 2 68Ga-DOTA-peptide uptake in high-grade gliomas does not correspond to SSTR2 immunohistochemistry. Axial fused PET/MR images 30
to 60 min post-injection, corresponding contrast-enhanced T1-weighted MR images, and tumor SSTR2 IHC from three different patients. Primary
glioblastoma (patient no. 17) presents 68Ga-DOTANOC uptake (A) and contrast-enhancement in MRI-T1-Gad (B). Patchy areas of positive SSTR2
staining were observed (C). Another primary glioblastoma (patient no. 15) also shows 68Ga-DOTANOC uptake (D) and contrast enhancement
(E). However, SSTR2 IHC was negative (F). Primary oligoastrocytoma (patient no. 10) represents no
68Ga-DOTANOC uptake (G) and no contrast
enhancement (H), but high SSTR2 expression in IHC was detected (I). Color scale in PET images is set to maximum (red) 10,000 Bq/ml and minimum
(blue) 0 Bq/ml. Bar = 50 μm.
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from IHC scoring with double staining. Due to intense
CD68 reactivity, however, the SSTR2 expression in
microglia and macrophages was not assessable. The dis-
tribution and number of microglia and macrophages
were heterogeneous. Within the cellular part of the
tumor, variable diffuse infiltration was observed, whereas
dense clusters of microglia and macrophages were de-
tected along the necrosis border in GBMs. The average
number of microglia and macrophages in anaplastic gli-
omas ranged from 0% to 4%, to 20% to 24% (median 5%
to 9%) and in GBMs from 10% to 14%, to 35% to 39%
(median 25% to 29%).
SSTR2 IHC, molecular markers, and survival
Positive SSTR2 IHC corresponded with IDH1 mutation
(P = 0.007), lower tumor grade (P = 0.005), and oligo-
dendroglioma component (P = 0.010) as presented in
Table 3. Furthermore, Ki67 was significantly lower inSSTR2-positive HGGs (14.44 ± 10.50) compared to
SSTR2-negative HGGs (41.05 ± 25.60; P = 0.001). Associ-
ation between SSTR2 IHC and MGMT promoter methy-
lation was not significant (P = 0.080), but it is notable
that all SSTR2-positive HGGs contained MGMT pro-
moter methylation, whereas all unmethylated HGGs
were SSTR2 negative. Positive SSTR2 IHC was related
to the absence of EGFR amplification (P = 0.021). How-
ever, no dependence was found between SSTR2 and
EGFR IHC.
Kaplan-Meier curves show the prognostic value of
SSTR2 status (Figure 3). Median PFS for SSTR2-posi-
tive and SSTR2-negative HGGs was 60.9 versus
10.9 months, respectively. Median OS for SSTR2-nega-
tive HGGs was 26.3 months. Only one death occurred
during follow-up among SSTR2-positive HGGs. Within
anaplastic gliomas, the median PFS for SSTR2-positive
and SSTR2-negative HGGs was 21.3 versus 12.7 months,
respectively.
Table 3 Crosstabs on SSTR2 immunohistochemistry (IHC)
against molecular markers, histological type, and tumor
grade
SSTR2 IHC
Negative Positive P value
n (%) n (%)
IDH1 mutation
Yes 3 (33.3) 6 (66.7) 0.007
No 16 (84.2) 3 (15.8)
1p/19q co-deletion
Yes 2 (50.0) 2 (50.0) 0.409
No 17 (70.8) 7 (29.2)
EGFR amplification
Yes 8 (100.0) 0 (0.0) 0.021
No 11 (55.0) 9 (45.0)
MGMT promoter methylation
Yes 13 (59.1) 9 (40.9) 0.080
No 5 (100.0) 0 (0.0)
p53 mutation
Yes 11 (78.6) 3 (21.4) 0.225
No 8 (57.1) 6 (42.9)
Grade
III 6 (42.9) 8 (57.1) 0.005
IV 13 (92.9) 1 (7.1)
Oligodendroglioma component
Yes 2 (28.6) 5 (71.4) 0.010
No 17 (81.0) 4 (19.0)
Figure 3 Survival in HGG patients separated by SSTR2 status in immunohis
overall survival (B) in HGG patients with positive or negative SSTR2 IHC. Ce
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for both PFS and OS (Table 4). SSTR2 expression was an
independent prognostic factor for prolonged PFS after
adjustment to histological grade (HR 0.161, CI 0.037 to
0.704, P = 0.015). Multivariate Cox regression for OS
was not applied due to a low number of end points.
IDH1 mutation and MGMT promoter methylation were
distinct prognostic factors for both PFS (HR 0.312, CI
0.102 to 0.950, P = 0.040 and HR 0.234, CI 0.073 to
0.753, P = 0.015, respectively) and OS (HR 0.167, CI
0.036 to 0.770, P = 0.022 and HR 0.229, CI 0.061 to
0.859, P = 0.029, respectively). Improved OS was ob-
served in patients younger than 60 years of age (HR
0.183, CI 0.053 to 0.631, P = 0.007).
Discussion
We have demonstrated that 68Ga-DOTA-peptide uptake
in PET/CT is associated to disrupted BBB but does not
correlate to immunohistochemically (IHC) determined
SSTR2 status, suggesting limited benefit of this approach
in defining suitable patients for PRRT. Low tumor SUV-
max further implies that the achievable dose with intra-
venously administered PRRT remains low. The second
finding of particular interest was the positive association
between SSTR2 expression and IDH1 mutation, oligo-
dendroglioma component, and improved PFS, which in-
dicates that SSTR2 expression may become a new
biomarker in HGG useful for prognostication and thera-
peutic decision-making.
Our findings correspond to SSTR scintigraphic studies
in low- and high-grade gliomas where 111In-DTPA-D-tochemistry. Kaplan-Meier curves for progression-free survival (A) and
nsored data are indicated by vertical lines.
Table 4 Univariate analysis of prognostic factors for progression-free survival (PFS) and overall survival (OS) in HGG
patients
PFS OS
n (%) HR (95% CI) P value HR (95% CI) P value
SSTR2 IHC
Negative 19 (67.9) 1 1
Positive 9 (32.1) 0.161 (0.037 to 0.704) 0.015 0.083 (0.010 to 0.655) 0.018
Age
> 60 11 (39.3) 1 1
< 60 17 (60.7) 0.484 (0.190 to 1.233) 0.128 0.183 (0.053 to 0.631) 0.007
Oligodendroglioma component
No 21 (75.0) 1 1
Yes 7 (25.0) 0.592 (0.210 to 1.672) 0.322 0.361 (0.094 to 1.380) 0.137
IDH1
Wild type 19 (67.9) 1 1
Mutated 9 (32.1) 0.312 (0.102 to 0.950) 0.040 0.167 (0.036 to 0.770) 0.022
MGMT promoter
Unmethylated 5 (18.5) 1 1
Methylated 22 (81.5) 0.234 (0.073 to 0.753) 0.015 0.229 (0.061 to 0.859) 0.029
1p/19q co-deletion
No 24 (85.7) 1 1
Yes 4 (14.3) 0.780 (0.244 to 2.496) 0.675 0.390 (0.081 to 1.871) 0.239
EGFR amplification
No 20 (71.4) 1 1
Yes 8 (28.6) 2.083 (0.819 to 5.297) 0.124 3.131 (0.986 to 9.943) 0.053
Results are expressed as hazard ratio (HR) with 95% confidence interval.
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disrupted BBB but did not correlate to in vitro SSTR
autoradiography [16]. The authors reasoned that this
discrepancy was due to nonspecific accumulation and
trapping of the octreotide molecules. Again, we did not
find a correlation between 68Ga-DOTA-peptide uptake
and SSTR2 IHC, which may be related to the heterogen-
eity of tumor tissue and uncertainties in obtaining the
tissue sample from regions with the highest tracer up-
take. Our results, however, do not confirm that the up-
take is merely due to nonspecific accumulation. First,
variation in SUVmax was noticed among similar MRI-
T1-Gad volumes (Figure 1C). Second, alteration in BP
values (range −0.62 to 3.33) suggests different SSTR2
densities in HGGs. Third, the Dice similarity coefficient
between tumor volumes in PET and MRI-T1-Gad was
rather low (0.41), implicating discordance between these
volumes. In other words, tracer uptake was not limited
to the area of disrupted BBB but was present in neigh-
boring areas due to diffusion and/or receptor binding.
Of note is also low expression of SSTR3 and SSTR5
which did not explain differences in tracer uptake. By
contrast, specific binding is not supported by the timecourse of tumor 68Ga-DOTA-peptide uptake (Figure 1A)
as the typical pattern of ligand-binding curve is not
present. Thus, nonspecific tracer uptake cannot be ex-
cluded since a blocking study requiring another dynamic
PET/CT was not performed.
The magnitude of diagnostic radionuclide uptake is
not trivial for a successful PRRT. In meningiomas
treated with PRRT, SUVmax with 68Ga-DOTA-peptides
was related to the corresponding 177Lu-labeled radio-
nuclide uptake and therapeutic dose [17]. SUVmax in
meningiomas ranged from 4.3 to 68.7 with a very low
therapeutic dose achieved with the lowest SUVmax. In
our study, mean SUVmax was 2.25 with only four GBMs
and one anaplastic glioma demonstrating SUVmax >3.0,
suggesting an insufficient achievable dose in PRRT. It
has to be noted, though, that PRRT in extra-axial men-
ingiomas is intravenously delivered whereas in gliomas
invading the brain, the therapeutic radionuclide needs to
be locally injected [2-4]. This is of importance especially
in HGGs with intact BBB that are SSTR2 positive but
lack tracer uptake in PET. These tumors may benefit
from locally delivered PRRT, which, however, cannot be
evaluated by intravenously given 68Ga-DOTA-peptides.
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first time that high SSTR2 expression in HGG is associ-
ated with IDH1 mutation which is regarded as the most
powerful prognostic marker for a favorable outcome
compared to IDH1 wild-type gliomas [18]. It is unclear,
however, why IDH1 mutation affects prognosis and what
the interaction with other markers is. Recently, IDH1
mutation was found to determine the prognostic and
predictive value of MGMT promoter methylation in ana-
plastic gliomas [19]. Association with mutant IDH1 im-
plicates a potential role for SSTR2 in the favorable
outcome of chemosensitive and radiosensitive HGGs.
This is substantiated by the observed trend of correl-
ation between SSTR2 expression and MGMT promoter
methylation.
Previous studies have not detected a clear association
between SSTR2 expression and oligodendroglioma com-
ponent. Cervera et al. found increased SSTR2 mRNA in
oligodendrogliomas but finally concluded that it was due
to contamination from normal brain [20]. Our SSTR2
scoring was based on IHC with a well-documented
monoclonal antibody UMB-1 allowing cellular localization
[21]. We found that SSTR2 staining was not restricted to
oligodendroglial tumor cells but was similarly present in
astrocytic cells in mixed oligoastrocytomas. Furthermore,
two anaplastic oligodendrogliomas out of the four HGGs
with 1p/19q co-deletion, a biomarker strongly linked to
oligodendroglial histology [22], also showed the most in-
tensive SSTR2 staining. We thus demonstrate an associ-
ation between SSTR2 and oligodendroglioma component
but underline that a larger study is necessary to confirm
this initial finding.
SSTR2 status was an independent prognostic marker
for PFS after adjustment to glioma grade. SSTR2 expres-
sion has previously been associated to improved survival
with neuroendocrine tumors [23] and childhood neuro-
blastomas [24], suggesting a potential role for SSTR2 as
a tumor suppressor. In fact, this antitumor effect has
been demonstrated in experimental pancreatic tumors
stably expressing SSTR2 [25], or after therapeutic SSTR2
gene transfer [26] with inhibited tumor growth. Our re-
sults on improved PFS substantiate the anti-oncogenic
role of SSTR2 in HGGs as well.
Our study confronts limitations. First, two tracers with
different affinity profiles for SSTR subtypes were used.
However, the highest affinity with both 68Ga-DOTANOC
and 68Ga-DOTATOC is for SSTR2 [27]. In addition, our
HGG samples demonstrated minimal expression of sub-
types SSTR3 and SSTR5, for which
68Ga-DOTANOC pos-
sesses higher affinity compared to 68Ga-DOTATOC. Also,
as 68Ga-DOTATOC was applied only in 3 patients and
68Ga-DOTANOC in 24 patients, we conclude that most
likely this limitation had little effect on the outcome. Sec-
ond, the number of patients was limited. Our data onestablished biomarkers, however, was in accordance with
current literature giving substantiation also to our SSTR2
results. Third, potential alteration in tumor edema affect-
ing volumetric analyses due to differences in steroid dos-
ing during the interval between MRI and PET/CT cannot
be excluded. Furthermore, clinical MRI with different
scanners and parameters was used for MRI-T1-Gad
evaluation.
Conclusions
We conclude that PET/CT with 68Ga-DOTA-peptides
provides limited value in identifying patients with SSTR2-
positive HGGs suitable for PRRT. Our study demonstrates
for the first time that SSTR2 expression in HGGs is associ-
ated with IDH1 mutation, oligodendroglioma component,
and improved PFS. This potential diagnostic and prognos-
tic value for SSTR2 expression in HGGs should be con-
firmed in a larger validation study.
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